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Summary We have used primary endocrine therapy for 61 elderly women with operable breast cancer
(median age 77 years). Eleven patients (18%) had complete and 24 (39%) partial tumour regression, 12 (20%)
had stable disease for a minimum of six months and 14 (23%) no response. Salvage surgery was undertaken
in the 14 with no response and 8/9 with progressive disease following initial response, thus samples were
available from relapse patients only. Assays for EGFr (two point radioreceptor assay) and oestrogen
receptors (ER) (dextran coated charcoal method and an immunohistochemical method) were performed on
20/22 patients. Ten of these 20 tumours were EGFr+ (>10 fmolmg- 1 binding) and 9/13 patients progressing
within six months had EGFr+ tumours. 15/22 were available for ER evaluation and there was no such
association with ER status. EGFr status was also associated with early recurrence after surgery and death in
the endocrine failure group (P<0.005 and P<0.05 respectively).
Of a control population of 33 patients (median age 72 years) treated by primary surgery, only 6 were
EGFr+. In this group early relapse was predicted by EGFr status, but not by ER status (median disease free
survival for EGFr+ patients 15 months, and for EGFr- patients 40 months, P<0.01, logrank test).
There was a significantly higher proportion of EGFr+ tumours in the endocrine failure group compared
with the control population (P<0.001).
EGFr status is a marker for rapid early progression on primary endocrine therapy and the development of
non-excisional methods of EGFr analysis would allow better directed therapeutic decisions.
The anti-oestrogen drug tamoxifen, and the aromatase inhi-
bitor aminoglutethimide, have been extensively tested in
metastatic breast cancer with overall objective remission
rates of around 30% (Cole & Todd, 1976; Ward, 1973;
Murray & Pitt, 1981; Harris et al., 1986a,b). The lack of
serious toxicity in the case of tamoxifen has made this a
particularly attractive therapy where quality of life was as
important as prolongation (Stewart et al., 1980). In
advanced disease ER status predicts response to endocrine
therapy (Block et al., 1975; McGuire et al., 1975; Roberts et
al., 1978).
The proportion of patients with ER positive primary
breast cancers increases with age such that about 70% of
patients over 70 years of age have ER positive tumours
(Allegra et al., 1979; Elwood & Godolphin, 1980). These
observations may in part account for the relatively good
prognosis for some elderly patients with breast cancer.
Tamoxifen had proved useful in the treatment of many
elderly patients with advanced or metastatic breast cancer
(Ingle et al., 1981; Legha et al., 1978). The use of pharma-
cological endocrine manipulation as the sole treatment of
primary operable breast cancer in the elderly has been
reported in several small studies (Preece et al., 1982;
Hellenberg et al., 1982; Bradbeer, 1985; Allan et al., 1985;
Horgan et al., 1986), and in one randomised prospective
study (Gazet et al., 1988), to be an alternative to surgery.
Steroid receptor status at relapse was not reported in these
studies but in one (Allan et al., 1985) the response rate for
ER positive tumours was found to be similar to the overall
response rate.
The use of primary endocrine therapy for many elderly
patients with operable breast cancer became our standard
practice in mid-1984. However, not all elderly patients will
respond to tamoxifen and some relapse rapidly (within 6
months) without any initial control of tumour growth. We
have shown previously that EGF receptor status is a strong
prognostic factor in primary breast cancer (Sainsbury et al.,
1987). Therefore, we have evaluated the relationship of
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EGFr to age, relapse in elderly patients on primary endo-
crine therapy, and its role in predicting tumour recurrence in
elderly patients treated by primary surgery.
Patients and methods
Fifty-one patients over seventy years and ten in their late
sixties with severe intercurrent medical illness or severe
psychological aversion to mastectomy who were otherwise
considered to have primary operable breast cancer were
offered primary endocrine therapy. Patients with proven
distant metastases at the time of presentation, as assessed by
biochemical and clinical criteria, were excluded from this
study.
The study population comprised 61 patients. The median
age was 77 years (range 64-96) and all patients were over 15
years postmenopausal. All the patients had confirmation of
the diagnosis by fine needle aspiration biopsy.
Primary endocrine therapy with either tamoxifen (20mg
once daily) (60 patients) or low dose aminoglutethimide
(125mg twice daily) and hydrocortisone (20mg twice daily)
was used. Three patients received low dose aminoglute-
thimide, one as primary therapy and two who had rapidly
progressed on tamoxifen.
Patients were assessed at three monthly intervals and
response was defined using UICC criteria (Hayward et al.,
1977). All responders (including static disease) had a follow-
up period of greater than 6 months. Median follow-up for
all patients was fourteen months. The 'no response' category
are patients who never showed evidence of a response
whereas patients who relapsed after a response are desig-
nated 'progression after initial response'.
At documented progression of the primary tumour (23
patients) the patient underwent surgical excision. Eighteen
patients had 'salvage' mastectomy, with axillary radiotherapy
if lymph node metastases were present. Four patients had a
wide lumpectomy followed by radical radiotherapy to the
breast, with a tumour bed boost by irridium wire implants.
One patient only with progressive local disease was not
treated surgically. She had a high axillary tail primary with a
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separate, but cytologically proven, axillary lymph node
metastasis. At progression she was treated by radical radio-
therapy with an irridium implant boost at the site of the
primary.
A control population of 33 elderly women, median age 72
years (range 64-86) with primary operable breast cancer
treated by primary surgery comprised historical controls who
received their treatment in the period immediately prior to
our adoption of primary endocrine therapy in this age group
and a small number of elderly patients under the care of
consultants not involved in this trial. Although this group
was slightly younger (median age 72 years compared with 77
years in the primary endocrine therapy group) there was no
difference in initial tumour size or disease stage compared
with the endocrine therapy group (Table I).
Following surgical excision for locally progressive disease
oestrogen receptor analysis was performed by the dextran
coated charcoal (DCC) method. A level of 5fmolmg- 1
cytosol protein was taken as the lower limit of positivity for
the DCC assay (Nicholson et al., 1988).
The DCC assay for ER was known to be affected by
pretreatment with tamoxifen (Taylor et al., 1982; Hull et al.,
1983; Crawford et al., 1987). If the DCC assay was positive
then the tumour was considered ER+. If the DCC assay was
negative then the ER status was evaluated by the immuno-
histochemical ER status. Frozen section immunohisto-
chemistry using a monoclonal antibody to the ER protein
(ERP 31 - Horne et al., unpublished) was performed on 13
tumours where frozen material was available. An indirect
immunoperoxidase technique was used to stain 7,um cryostat
sections. The slides were assessed for nuclear staining. If
greater than ten percent of the cells in a field exhibited
nuclear staining the tumour was graded ER positive. The ER
status could be evaluated on 15/22 tumours excised for
progression on endocrine therapy.
Epidermal growth factor receptor (EGFr) analysis was
performed on 20/22 patients with progression on primary
endocrine therapy using a two point 1-125 EGF radio-
receptor assay with lOfmolmg-1 the lower limit of binding
considered positive (Nicholson et al., 1988).
All the control patients had ER and EGFr assays per-
formed on their primary tumours. None had received prior
endocrine therapy, therefore, ER immunohistochemistry was
not necessary for assessment of these tumours.
Statistics
Peto life table analysis was performed using a Logrank test
(Peto et al., 1977) with a programme designed for the BBC
microcomputer by Dr B. Angus (Dept. Pathology, Univer-
sity of Newcastle upon Tyne). The Chi-square and Fisher's
Exact tests were used to compare populations in the various
subgroups.
Results
Response to endocrine therapy
Of sixty-one patients commenced on primary endocrine
therapy eleven achieved a complete response (CR), twenty-
four a partial response (PR), twelve had static disease (SD)
and fourteen had progressive disease (PD) (Table II).
For patients achieving a partial response the median time
to establish this was 3 months, and for those achieving a
complete response it was 10 months.
There was only one death in the patients with a continuing
response. This patient was 91 at presentation and died of
causes unrelated to her breast cancer. There were 7 deaths in
the group undergoing salvage surgery, all from disseminated
breast cancer.
Comparison of outcome in control vs. primary endocrine
patients
Recurrence for the primary endocrine patients was con-
Table I Comparison of study and control populations
Primary endocrine Primary surgery
Number 61 33
Median age (yrs) 77 72
Age range (yrs) 64-96 64-86
% clinical stage I 70 73
Mean tumour diameter (cm) 3 3
% tissue available for
receptor assay (n) 33 (20/61) 100 (33/33)
% EGFr+ (n) 50 (10/20) 18 (6/33)'
% ER+ (n) 60 (9/15) 67 (22/33)b
aChi-square (2 x 2, Yates corrected) =4.5, P<0.04; bChi-square
(2 x 2, Yates corrected)=0.59, not significant.
Table II Response to primary endocrine therapy
No. patients (%) Tissue available
Complete response 11 (18)
Partial response 24 (39) 4
Static disease 12 (20) 4
No response 14 (23) 12
61 (100) 20
sidered to be the development of recurrent tumour following
salvage surgery and/or radiotherapy. There was no signifi-
cant difference in recurrence free survival (RFS) measured
from the start of therapy (primary endocrine or primary
surgery) between the primary endocrine and primary surgical
therapy groups (Figure la). Similarly, there was no signifi-
cant difference in overall survival (OS) between the two
groups (Figure lb). There were 5 deaths in the control
group, all from disseminated breast cancer.
Comparison of receptor status between control and primary
endocrine therapy patients undergoing salvage surgery
Twenty-three patients commencing on primary endocrine
therapy showed progression of their primary tumours, 14
without any initial response and 9 who had initially res-
ponded, and then progressed. Twenty-two had surgical treat-
ment and EGFr were measured in twenty. ER status was
evaluable in fifteen patients. EGFr and ER status was
known in all the control patients. A comparison of the
receptor status in the salvage surgery and primary surgery
control groups is shown in Table I.
EGFr status: association with progression on primary
endocrine therapy
Of 23 patients showing no response or progression after
initial response, 13 progressed within six months. Eleven of
these had EGFr assays and nine were EGFr+ (Figure 2a). In
contrast, this early relapse group was composed of similar
numbers of ER+ and ER- tumours (Figure 2b). None of
the EGFr+ patients had any objective response prior to
disease progression.
A comparison of receptor status among the 'salvage'
surgery patients is shown in Table III. There is a significant
association with EGFr positivity and failure of any response
to endocrine therapy. In contrast 6/7 relapsers after an initial
response were ER+ at relapse and none were EGFr+.
The proportion of patients with EGFr+ tumours was
significantly different in those progressing on primary endo-
crine therapy from that found in the general elderly popula-
tion, as exemplified by the primary surgical control group
(Table III).
Poor prognosis associated with progression on primary
endocrine therapy
Recurrence free survival (RFS) or time to first recurrence in
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Figure 1 (a) Recurrence free survival: Primary endocrine
therapy compared with primary surgical therapy; (b) Overall
survival: Primary endocrine therapy compared with primary
surgical therapy.
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Figure 2 (a) Response to primary endocrine therapy with EGFr
status of endocrine failure patients measured at 'salvage' surgery;
(b) Response to primary endocrine therapy with ER status of
endocrine failure patients measured at 'salvage' surgery.
Table III Receptor status of 'salvage' surgical patients
Progression after
Receptor status No response initial response
ER+
ER-
therapy ('no response' and 'progression after initial res-
ponse') was taken as the time from diagnosis (and therefore
start of endocrine therapy) to documented first recurrence
after surgery. RFS for the control group was obviously time
from surgery to first recurrence. Overall survival (OS) was
assessed in a similar way. None of the primary endocrine
responders (CR, PR and SD) have so far developed evidence
of relapse at distant sites prior to documented progression of
the primary. As expected both RFS and OS were less in the
endocrine progressive disease group compared to the
controls (chi-square= 19.82, P<0.001 and 13.64, P<0.005
respectively, logrank).
EGFr status: association with recurrence after 'salvage
surgery' and death in primary endocrine failure patients
EGFr status was significantly associated with recurrence
after salvage surgery and death (timed from the start of
endocrine therapy) for the endocrine progressive disease
patients (chi-square for recurrence =7.92, P<0.005, Figure
3a, and death=4.31, P<0.05, Figure 3b). There was no such
association for ER status.
In the control primary surgery patients EGFr status also
predicted recurrence (chi-square=7.11, P<0.01, Figure 4).
The relationship between overall survival and EGFr status,
however, did not reach significance. ER status did not
predict recurrence or death in the control group.
The RFS of the EGFr positive endocrine progressive
disease patients was similar to the EGFr positive control
3
5
Controls
22
11
Fisher's Exact 2 x 2, P<0.1; Chi-square no responses vs. controls
(2 x 2)=1.239, not significant
EGFr+ 10 0 6
EGFr- 2 8 27
Fisher's Exact 2 x 2, P<0.001; Chi-square no response vs. controls
(2 x 2)= 13.58, P<0.001.
patients and likewise the EGFr negative patients in both
groups had similar recurrence free survivals (Figure 4).
Discussion
This prospective study of primary endocrine therapy in an
elderly postmenopausal group of patients with operable
breast cancer did reveal similar results to other published
series with an overall response rate of 77% Overall survival
in the endocrine treated patients was similar to that in the
control group. This finding was reported recently in a
prospective, randomised study of endocrine therapy vs.
surgery in elderly patients (Gazet et al., 1988).
We have evaluated the interaction of EGFr and ER in
relation to failure of response to hormone therapy. It is not
known if previous endocrine therapy may alter EGFr status.
There were, however, six EGFr+ tumours in a control
population of 33 patients which was comparable to the study
group for disease stage and lower limit of age (Table I). If a
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Figure 3 (a) Recurrence (after salvage surgery) free survival for
endocrine failure patients timed from start of primary therapy
stratified by EGFr status; (b) Overall survival for endocrine
failure patients timed from start of primary therapy stratified by
EGFr status.
Table IV Variation of receptor status with age
Age % EGFr+ (n) % ER+ (n)
<40 38.5 (10) 34.5 (9)
40-54 48 (41) 37.5 (32)
55-69 32 (31) 52 (50)
>70 17 (6) 71.5 (25)
All ages 36 (88) 48 (118)
similar percentage were in the primary endocrine population
there would be eleven EGFr+ tumours in a population of 61
patients. Since there were ten EGFr+ tumours in the PD
group, pretreatment did not appear to affect EGFr expres-
sion in this elderly population.
EGF receptor assays have not previously been performed
on patients who failed to respond to primary endocrine
therapy. Fifty percent of the patients in the endocrine failure
group (n=20) were EGFr+, compared to only 18% of the
control group (P<0.04). The proportion of EGFr+ tumours
in the control group is lower than that previously reported in
a series of 246 tumours (Nicholson et al., 1988). The
proportion of patients with ER+ tumours is known to be
related to age (Elwood & Godolphin, 1980). We have
therefore compared ER and EGFr expression with age in
our previously published series of primary operable breast
cancers (Nicholson et al., 1988). The inverse relationship to
Time (months)
Patients at risk at start and at intervals of 6 months thereafter
EGFr 0 6 12 18 24 30 36 42
Endocrine -10 9 9 8 5 4 2 0
failures + 10 8 3 2 2 1 0 0
Primary - 27 27 21 16 14 12 8 5
surgery + 6 5 4 1 1 0 0 0
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0
Figure 4 Recurrence free survival timed from the start of
primary therapy for endocrine failure and primary surgical
patients stratified by EGFr status.
ER status is maintained at all ages (Table IV) and there is a
significant inverse correlation of EGFr with age (P<0.01).
Previous follow-up studies had shown that EGFr status of
primary operable breast tumours was associated with a
poorer prognosis (Sainsbury et al., 1987). The current study
has confirmed these findings in an elderly primary surgical
control population.
The data from this study has shown an association
between EGFr status at the time of 'salvage' surgery and
reduced RFS (time from start of primary endocrine therapy
to post-surgical relapse) and OS in patients whose disease
had progressed on primary endocrine therapy.
EGFr status was significantly associated with a lack of
any response to primary endocrine therapy. Twenty out of
twenty-two patients undergoing 'salvage' surgery for endo-
crine progressive disease had EGFr analysis. Ten of twelve
patients whose tumours had shown no response to primary
endocrine therapy were EGFr+ compared with none ofeight
patients whose tumours progressed after an initial response
(P=0.0014). There was no such association with ER status
which was similarly not associated with either RFS or OS in
either the endocrine progressive disease or control
populations.
Since 9/11 tumours progressing on primary endocrine
therapy within six months of the start of therapy were
EGFr+ this suggests that EGFr expression is associated with
rapid failure of endocrine therapy. It was not possible to
evaluate EGFr status before therapy in this particular group
because the aim was to minimise traumatic intervention and
perform fine needle aspiration biopsy before starting endo-
crine therapy.
Surgical treatment at an earlier stage when the primary
tumour was smaller would be less traumatic for these elderly
patients. However, since surgical failures and endocrine
therapy failures which have EGFr+ tumours have very
similar prognosis, surgery of endocrine failures per se seems
to have relatively little to offer other than debulking tumour
and improving the chances of local control. At relapse
following surgery, or perhaps even as an adjuvant therapy, a
mild short course chemotherapy, such a mitozantrone,
should be evaluated (Cantwell et al., 1987).
The value of EGFr data in identifying a population of
elderly breast cancer patients who progressed rapidly on
primary endocrine therapy and surgery highlighted the need
to develop non-excisional methods of receptor analysis. The
radioreceptor assay for EGFr used in this study required
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more tumour material than could be provided by needle core
biopsy. Immunological methods using a monoclonal anti-
body to the EGF receptor (Waterfield et al., 1982) to stain
fine needle aspiration biopsy smears may prove to be useful.
S. Nicholson is funded by the North of England Cancer Campaign.
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